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Scientific background
Due to the important physiologic function of trivalent
chromium in glucose/insulin homeostasis, some com-
mercial organisations promote Cr3+ supplements in
maintaining proper carbohydrate and lipid metabolism;
regulation of reducing carbohydrate carvings and appe-
tite; prevention of insulin resistance and glucose intoler-
ance; regulation of body composition, including
reducing fat mass and increasing lean body mass; opti-
mal body building for athletes; losing weight; treatment
of atypical depression as an antidepressant; and preven-
tion of obesity and type 2 diabetes mellitus. On one
hand, case reports are commented as ‘nonevidence-
based anecdotes’. On the other hand, a number of inde-
pendent studies warn against adverse health outcomes
assigned to chromium picolinate (CrPic) dietary applica-
tion [1].
Materials and methods
To simulate treatment affects by CrPic a well-acknowl-
edged animal diabetes model of db/db-mice was utilised.
Animals were grouped into eight groups. Group 1 repre-
sented the healthy control. Group 2 was the model mice
for type 2 DM. Groups 3 - 7 were diabetes-model mice
treated under individual algorithms: 5 mg/kg CrPic from
6 weeks to 6 months of age (Group 3), 10 mg/kg CrPic
from 6 weeks to 6 months of age (Group 4), 100 mg/kg
CrPic from 6 weeks to 6 months of age (Group 5), 100
mg/kg CrPic from 3 months to 6 months of age (Group
6), and 250 mg/kg CrPic from 3 months to 6 months of
age (Group 7). Kidney tissue samples were collected and
stored at - 80°C till quantitative comet assay sub-cellular
imaging was performed to evaluate individual and
group-specific effects by CrPic treatments.
Results
We have demonstrated highly individual reactions
towards CrPic dietary supplements and highlighted risks
when the dietary supplements are used freely as thera-
peutic agents, without application of advanced diagnos-
tic tools to predict individual outcomes (Figure 1) [2].
Conclusions and recommendations: artificial
supplements for diabetes prevention - hype or
hope?
High efficacy of a balanced diet, an individually opti-
mised lifestyle and personalised treatment regiments can
hardly be substituted by a limited number of single sup-
plements to cover all the multifactorial risks such as the
upward trends of population ageing, environmental risk
factors, urbanisation, additive effects of diverse stress
factors, incorrectly chosen lifestyle including unfavour-
able nutritional habits, increasing prevalence of obesity,
low physical activity, etc [3]. The population at-risk for
diabetes is huge and increasing in a pandemic scale.
One of the reasons might be the failed attempt to pre-
vent the disease by the application of artificial supple-
ments and drugs with hardly recognised individual risks.
Consequently, a multimodal approach of integrative
medicine by predictive diagnostics, targeted prevention
and individually created treatment algorithms is highly
desirable. Targeted measures require a creation of new
guidelines that are essential to regulate (renoprotective)
therapy approaches and the application of more indivi-
dualised therapeutic modalities for advanced diabetes
care. These measures should provide a legitimate regula-
tion for well-timed predictive diagnostics, an effective
prevention and the creation of individualised treatment
algorithms in pre/diabetes care [4].
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Figure 1 Diagram demonstrates individual reactions towards CrPic treatments in the groups of comparison. Individual levels of intact DNA (axe
X, individual numbering; axe Y, comet class I in %) are highly heterogeneous in diabetic groups compared to control group 1. The highest level
of heterogeneity is evident in groups 5, 6 and 7 with the highest doses of CrPic supplements. The turquoise lines mark the level corresponding
to the mean value of the control group; in contrast, the red arrows mark the level corresponding to the mean of the untreated diabetic
group [2].
Golubnitschaja et al. EPMA Journal 2014, 5(Suppl 1):A77
http://www.epmajournal.com/content/5/S1/A77
Page 2 of 3
Acknowledgements
The project has been granted by NIH (“Is chromium-picolinate
renoprotective in diabetes?”, National Institutes of Health, study no. 1R21
AT003012-01A1). The authors thank to Prof. Dr. M. Mozaffari (Georgia Health
Sciences University, USA) for providing tissue samples in the project. For the
statistical analysis and assistance in preparation of the original paper [5], the
authors thank V. Peeva, M.Sc., University of Bonn, Germany.
Published: 11 February 2014
References
1. Yeghiazaryan K, Schild HH, Golubnitschaja O: Recognition of individual
risks by analysis of subcellular imaging insights into chromium
picolinate therapy in pre/diabetes care, search into its safety and
opinion controversy. New Strategies to Advance Pre/Diabetes Care:
Integrative Approach by PPPM in Diabetes Edited by Mozaffari M; Book-Series
“Advances in Predicitive, Preventive and Personalised Medicine” Springer; 2013.
2. Golubnitschaja O, Yeghiazaryan K: Opinion controversy to chromium
picolinate therapy’s safety and efficacy: ignoring ‘anecdotes’ of case
reports or recognising ndividual risks and new guidelines urgency to
introduce innovation by predictive diagnostics? EPMA J 2012, 3:11.
3. Yeghiazaryan K, Cebioglu M, Golubnitschaja O: Global Figures Argue in
Favour of Preventive Measures and Personalised Treatment to Optimise
Inadequate Diabetes Care. In New Strategies to Advance Pre/Diabetes Care:
Integrative Approach by PPPM. Springer;Mozaffari M 2013:.
4. Golubnitschaja O, Costigliola V: Common origin but individual outcomes:
time for new guidelines in personalized healthcare. Personalized Med
2010, 7:561-568.
5. Yeghiazaryan K, Peeva V, Shenoy A, Schild HH, Golubnitschaja O:
Chromium-picolinate therapy in diabetes care: molecular and subcellular
profiling revealed a necessity for individual outcome prediction,
personalised treatment algorithms and new guidelines. Infect Disord Drug
Targets 2011, 11:188-195.
doi:10.1186/1878-5085-5-S1-A77
Cite this article as: Golubnitschaja et al.: Chromium picolinate therapy in
pre/diabetes care: recognition of individual risks and outcomes. EPMA
Journal 2014 5(Suppl 1):A77.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Golubnitschaja et al. EPMA Journal 2014, 5(Suppl 1):A77
http://www.epmajournal.com/content/5/S1/A77
Page 3 of 3
